Retatrutide (LY3437943) is the GLP-1, GIP and glucagon receptor triple agonist developed by Eli Lilly and one of the most actively studied investigational peptides in late-stage metabolic research. PeptX supplies research-grade Retatrutide at manufacturer-stated 99%+ purity to UK academic and private research groups, with GBP pricing and tracked UK domestic dispatch.
View the full PeptX research peptide catalogue, or browse Retatrutide, Tirzepatide, Semaglutide, BPC-157, TB-500 and GHK-Cu.